MCID: PLY041
MIFTS: 57

Polymyositis

Categories: Rare diseases, Respiratory diseases, Neuronal diseases, Nephrological diseases, Bone diseases

Aliases & Classifications for Polymyositis

MalaCards integrated aliases for Polymyositis:

Name: Polymyositis 49 50 55 51 69
Pm 55

Characteristics:

Orphanet epidemiological data:

55
polymyositis
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe),1-9/1000000 (Argentina),1-9/100000 (Argentina),1-9/1000000 (Australia),1-9/100000 (Australia),1-9/1000000 (Spain),1-9/1000000 (Sweden); Age of onset: Adult,Elderly; Age of death: adult;

Classifications:



Summaries for Polymyositis

NIH Rare Diseases : 49 Polymositis is a type of inflammatory myopathy, which refers to a group of muscle diseases characterized by chronic muscle inflammation and weakness. The muscles affected by polymyositis are the skeletal muscles (those involved with making movements) on both sides of the body. Although the disease can affect people of all ages, most cases are seen in adults between the ages of 31 and 60 years. The disease is more common among women and among black individuals.  The exact cause of polymyositis is unknown. The disease shares many characteristics with autoimmune disorders, which occur when the immune system mistakenly attacks healthy body tissues. In some cases, the disease may be associated with viral infections, connective tissue disorders, or an increased risk for malignancies (cancer). Diagnosis is based on a clinical examination that may include laboratory tests, imaging studies, electromyography, and a muscle biopsy. Although there is no cure for polymyositis, treatment with corticosteroids or immunosuppressants can improve muscle strength and function. Last updated: 9/25/2017

MalaCards based summary : Polymyositis, also known as pm, is related to antisynthetase syndrome and myositis, and has symptoms including abnormality of the renal tubule, chondrocalcinosis and muscular hypotonia. An important gene associated with Polymyositis is HARS (Histidyl-TRNA Synthetase), and among its related pathways/superpathways are tRNA Aminoacylation and Interleukin-10 signaling. The drugs Abatacept and Pirfenidone have been mentioned in the context of this disorder. Affiliated tissues include lung, heart and testes, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

NINDS : 50 Polymyositis is one of a group of muscle diseases known as the inflammatory myopathies, which are characterized by chronic muscle inflammation accompanied by muscle weakness.  Polymyositis affects skeletal muscles (those involved with making movement) on both sides of the body.  It is rarely seen in persons under age 18; most cases are in adults between the ages of 31 and 60.  Progressive muscle weakness starts in the proximal muscles (muscles closest to the trunk of the body) which eventually leads to difficulties climbing stairs, rising from a seated position, lifting objects, or reaching overhead.  People with polymyositis may also experience arthritis, shortness of breath, difficulty swallowing and speaking, and heart arrhythmias.  In some cases of polymyositis, distal muscles (muscles further away from the trunk of the body, such as those in the forearms and around the ankles and wrists) may be affected as the disease progresses.  Polymyositis may be associated with collagen-vascular or autoimmune diseases, such as lupus.  Polymyositis may also be associated with infectious disorders, such as HIV-AIDS.

Wikipedia : 72 Polymyositis (PM) is a type of chronic inflammation of the muscles (inflammatory myopathy) related to... more...

Related Diseases for Polymyositis

Diseases in the Polymyositis family:

Juvenile Polymyositis

Diseases related to Polymyositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 262)
# Related Disease Score Top Affiliating Genes
1 antisynthetase syndrome 32.4 HARS KARS
2 myositis 31.2 AARS CHKB HARS MB PIK3C2A
3 metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration 29.7 CHKB MB PIK3C2A
4 acute myocardial infarction 28.9 CHKB MB PIK3C2A
5 dermatomyositis 28.5 AARS CHKB GARS HARS IARS ICAM1
6 myocardial infarction 28.5 CHKB ICAM1 MB PIK3C2A
7 silicosis 28.1 IL1A SFTPD
8 juvenile polymyositis 12.3
9 mixed connective tissue disease 11.4
10 childhood type dermatomyositis 11.2
11 idiopathic inflammatory myopathy 11.2
12 tropical spastic paraparesis 11.2
13 myelopathy, htlv-1-associated 11.2
14 retrovirus-associated myelopathy 10.9
15 lung disease 10.3
16 interstitial lung disease 10.3
17 inclusion body myositis 10.2
18 virus associated hemophagocytic syndrome 10.2 MB PIK3C2A
19 interstitial myocarditis 10.2 MB PIK3C2A
20 posterior myocardial infarction 10.2 MB PIK3C2A
21 myositis fibrosa 10.2 MB PIK3C2A
22 anuria 10.1 MB PIK3C2A
23 myopathy 10.1
24 plexopathy 10.1 MB PIK3C2A
25 pneumonia 10.1
26 intermediate coronary syndrome 10.1 MB PIK3C2A
27 arthritis 10.1
28 scleroderma, familial progressive 10.1
29 acute mountain sickness 10.1 MB PIK3C2A
30 pseudohyperkalemia, familial, 2, due to red cell leak 10.1 MB PIK3C2A
31 subendocardial myocardial infarction 10.0 ICAM1 MB
32 rheumatoid arthritis 10.0
33 dengue disease 10.0 ICAM1 PIK3C2A
34 sebaceous gland disease 10.0 AARS IL1A
35 hepatitis 10.0
36 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.0
37 myoglobinuria 10.0 MB PIK3C2A
38 pericardial effusion 10.0 CHKB PIK3C2A
39 myocarditis 10.0
40 limbal stem cell deficiency 10.0 ICAM1 IL1A
41 lupus erythematosus 9.9
42 lymphoma 9.9
43 connective tissue disease 9.9
44 cholesteatoma of middle ear 9.9 ICAM1 IL1A
45 systemic lupus erythematosus 9.9
46 adult dermatomyositis 9.9
47 thymoma 9.9
48 thymoma, familial 9.9
49 charcot-marie-tooth disease 9.9 AARS GARS HARS KARS
50 creatine phosphokinase, elevated serum 9.9 CHKB MB PIK3C2A

Comorbidity relations with Polymyositis via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Dermatomyositis Heart Disease
Hypertension, Essential Hypothyroidism
Osteoporosis Temporal Arteritis

Graphical network of the top 20 diseases related to Polymyositis:



Diseases related to Polymyositis

Symptoms & Phenotypes for Polymyositis

Human phenotypes related to Polymyositis:

55 31 (show all 42)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormality of the renal tubule 55 31 occasional (7.5%) Occasional (29-5%) HP:0000091
2 chondrocalcinosis 55 31 occasional (7.5%) Occasional (29-5%) HP:0000934
3 muscular hypotonia 55 31 hallmark (90%) Very frequent (99-80%) HP:0001252
4 gait disturbance 55 31 occasional (7.5%) Occasional (29-5%) HP:0001288
5 reduced tendon reflexes 55 31 occasional (7.5%) Occasional (29-5%) HP:0001315
6 arthritis 55 31 frequent (33%) Frequent (79-30%) HP:0001369
7 dysphonia 55 31 occasional (7.5%) Occasional (29-5%) HP:0001618
8 congestive heart failure 55 31 occasional (7.5%) Occasional (29-5%) HP:0001635
9 hypertrophic cardiomyopathy 55 31 occasional (7.5%) Occasional (29-5%) HP:0001639
10 dilated cardiomyopathy 55 31 occasional (7.5%) Occasional (29-5%) HP:0001644
11 myocardial infarction 55 31 occasional (7.5%) Occasional (29-5%) HP:0001658
12 pericarditis 55 31 occasional (7.5%) Occasional (29-5%) HP:0001701
13 weight loss 55 31 frequent (33%) Frequent (79-30%) HP:0001824
14 fever 55 31 frequent (33%) Frequent (79-30%) HP:0001945
15 constipation 55 31 frequent (33%) Frequent (79-30%) HP:0002019
16 gastroesophageal reflux 55 31 occasional (7.5%) Occasional (29-5%) HP:0002020
17 abdominal pain 55 31 occasional (7.5%) Occasional (29-5%) HP:0002027
18 anorexia 55 31 frequent (33%) Frequent (79-30%) HP:0002039
19 respiratory insufficiency 55 31 frequent (33%) Frequent (79-30%) HP:0002093
20 pulmonary fibrosis 55 31 occasional (7.5%) Occasional (29-5%) HP:0002206
21 gastrointestinal hemorrhage 55 31 occasional (7.5%) Occasional (29-5%) HP:0002239
22 hepatomegaly 55 31 occasional (7.5%) Occasional (29-5%) HP:0002240
23 vasculitis 55 31 occasional (7.5%) Occasional (29-5%) HP:0002633
24 arthralgia 55 31 hallmark (90%) Very frequent (99-80%) HP:0002829
25 exertional dyspnea 55 31 frequent (33%) Frequent (79-30%) HP:0002875
26 autoimmunity 55 31 hallmark (90%) Very frequent (99-80%) HP:0002960
27 breast carcinoma 55 31 occasional (7.5%) Occasional (29-5%) HP:0003002
28 elevated serum creatine phosphokinase 55 31 hallmark (90%) Very frequent (99-80%) HP:0003236
29 myalgia 55 31 frequent (33%) Frequent (79-30%) HP:0003326
30 emg abnormality 55 31 hallmark (90%) Very frequent (99-80%) HP:0003457
31 proximal muscle weakness 55 31 hallmark (90%) Very frequent (99-80%) HP:0003701
32 abnormality of muscle fibers 55 31 hallmark (90%) Very frequent (99-80%) HP:0004303
33 venous thrombosis 55 31 occasional (7.5%) Occasional (29-5%) HP:0004936
34 abnormal atrioventricular conduction 55 31 occasional (7.5%) Occasional (29-5%) HP:0005150
35 interstitial pulmonary abnormality 55 31 frequent (33%) Frequent (79-30%) HP:0006530
36 arrhythmia 55 31 occasional (7.5%) Occasional (29-5%) HP:0011675
37 fatigue 55 31 frequent (33%) Frequent (79-30%) HP:0012378
38 elevated aldolase level 55 31 hallmark (90%) Very frequent (99-80%) HP:0012544
39 cough 55 31 hallmark (90%) Very frequent (99-80%) HP:0012735
40 abnormality of the voice 55 Occasional (29-5%)
41 abnormality of the mitral valve 55 Occasional (29-5%)
42 abnormal mitral valve morphology 31 occasional (7.5%) HP:0001633

GenomeRNAi Phenotypes related to Polymyositis according to GeneCards Suite gene sharing:

25 (show all 15)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-109 9.58 GARS
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 9.58 IARS KARS
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.58 GARS
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-160 9.58 KARS
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 9.58 KARS GARS IARS
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 9.58 GARS
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.58 IARS
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 9.58 IARS
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.58 KARS
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-211 9.58 KARS
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 9.58 KARS
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-26 9.58 GARS
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.58 GARS
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 9.58 KARS
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-87 9.58 GARS

Drugs & Therapeutics for Polymyositis

Drugs for Polymyositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 121)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Abatacept Approved Phase 4,Phase 3,Phase 2 332348-12-6 10237
2
Pirfenidone Approved, Investigational Phase 4 53179-13-8 40632
3 beta-endorphin Phase 4,Phase 2
4 Adrenocorticotropic Hormone Phase 4,Phase 2
5 Vaccines Phase 4
6 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
7 Hormones Phase 4,Phase 3,Phase 2,Phase 1
8 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
9 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
10 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
11 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
12 Melanocyte-Stimulating Hormones Phase 4,Phase 2
13 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
14 Analgesics Phase 4,Phase 2,Phase 3,Phase 1
15 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1
16 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3,Phase 1
17
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
18
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
19
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2 22916-47-8 4189
20
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
21
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
22
Levoleucovorin Approved, Investigational Phase 3,Phase 2 68538-85-2
23
Tacrolimus Approved, Investigational Phase 2, Phase 3 104987-11-3 445643 439492
24
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 50-18-0, 6055-19-2 2907
25
Alendronate Approved Phase 3 121268-17-5, 66376-36-1 2088
26
Etanercept Approved, Investigational Phase 2, Phase 3,Phase 1 185243-69-0
27
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
28
Infliximab Approved Phase 2, Phase 3 170277-31-3
29
Benzocaine Approved, Investigational Phase 2, Phase 3 1994-09-7, 94-09-7 2337
30
belimumab Approved Phase 2, Phase 3 356547-88-1 5957 10451420
31
Acetylcysteine Approved, Investigational Phase 2, Phase 3 616-91-1 12035
32
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
33
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
34
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
35 tannic acid Approved, Nutraceutical Phase 2, Phase 3
36
Alfacalcidol Approved, Nutraceutical Phase 3 41294-56-8 5282181
37 Prednisolone acetate Phase 3,Phase 2
38 glucocorticoids Phase 3,Phase 2,Phase 1
39 Methylprednisolone acetate Phase 3,Phase 2
40 Methylprednisolone Hemisuccinate Phase 3,Phase 2
41 Folic Acid Antagonists Phase 3,Phase 2
42 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
43 Neuroprotective Agents Phase 3,Phase 2
44 Cyclosporins Phase 3,Phase 2
45 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
46 Dermatologic Agents Phase 3,Phase 2
47 Vitamin B Complex Phase 3,Phase 2
48 Antiemetics Phase 3,Phase 2
49 Anti-Infective Agents Phase 3,Phase 2,Phase 1
50 Antifungal Agents Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 84)

# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
2 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
3 Abatacept in Juvenile Dermatomyositis Recruiting NCT02594735 Phase 4 Abatacept
4 Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis Recruiting NCT02245841 Phase 4 H.P. Acthar Gel
5 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Active, not recruiting NCT03226119 Phase 4
6 Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Not yet recruiting NCT02821689 Phase 4 Pirfenidone
7 Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis Unknown status NCT00323960 Phase 3 3 MPDN pulse + PDN;3 MPDN pulse + PDN + CSA;3 MPDN pulse + PDN + MTX
8 Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM) Completed NCT00335985 Phase 3 GB-0998;Placebo of GB-0998
9 Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM Completed NCT00651040 Phase 3 Prednisone;Methotrexate
10 Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus Completed NCT00504348 Phase 2, Phase 3 Tacrolimus
11 Anakinra in Myositis Completed NCT01165008 Phase 2, Phase 3 Anakinra
12 Treatment With TNF Blockade, Infliximab, in Patients With Myositis Completed NCT00443222 Phase 2, Phase 3 Infliximab
13 Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Completed NCT00138983 Phase 3 Alendronate versus alfacalcidol (1-alpha OH vitamin D)
14 Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD Recruiting NCT01862926 Phase 2, Phase 3 Rituximab;Cyclophosphamide
15 Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy Recruiting NCT02971683 Phase 3 Abatacept subcutaneous;Placebo
16 Belimumab in Myositis Recruiting NCT02347891 Phase 2, Phase 3 Belimumab;Placebo
17 Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy) Recruiting NCT02728752 Phase 3 Octagam 10%
18 A Clinical Trial for CTD-ILD Treatment Terminated NCT01424033 Phase 2, Phase 3 N-Acetylcysteine
19 Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis Terminated NCT00035958 Phase 2, Phase 3 Prednisone;Methotrexate;Etanercept
20 Abatacept Treatment in Polymyositis and Dermatomyositis Unknown status NCT01315938 Phase 2 Abatacept;Abatacept
21 Acthar in Treatment of Refractory Dermatomyositis and Polymyositis Completed NCT01906372 Phase 2 Adrenocorticotropic Hormone Gel
22 Efficacy of an Individual Rehabilitation Program in Polymyositis and Dermatomyositis Completed NCT01415219 Phase 2
23 Methimazole to Treat Polymyositis and Dermatomyositis Completed NCT00001421 Phase 2 methimazole
24 Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis Completed NCT00033891 Phase 2 Infliximab
25 Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) Completed NCT00106184 Phase 2 Rituximab;Placebo
26 Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies Completed NCT00001261 Phase 2 Gamma Globulin
27 A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis Completed NCT00979654 Phase 2 Sifalimumab
28 Safety and Efficacy of BAF312 in Dermatomyositis Completed NCT02029274 Phase 2 BAF312 0.5 mg;BAF312 2 mg;BAF312 10 mg;Placebo to BAF312
29 Topical Sodium Thiosulfate and Fractional Carbon Dioxide Laser in Treating Dermatomyositis Associated Calcinosis Completed NCT01572844 Phase 2 Sodium thiosulfate
30 Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis Completed NCT00005571 Phase 2 h5G1.1-mAb
31 Absorption of Corticosteroids in Children With Juvenile Dermatomyositis Completed NCT00004357 Phase 2 Methylprednisolone;Prednisolone
32 Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis Recruiting NCT02043548 Phase 2 tocilizumab;placebo
33 A Study In Adults With Moderate To Severe Dermatomyositis Recruiting NCT03181893 Phase 2 PF-06823859;Placebo Arm
34 Study of IFN-K in Dermatomyositis Recruiting NCT02980198 Phase 2
35 Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis Recruiting NCT03267277 Phase 2 Sodium Thiosulfate
36 Trial of IMO-8400 in Adult Patients With Dermatomyositis Active, not recruiting NCT02612857 Phase 2 IMO-8400 Dose Group 1;IMO-8400 Dose Group 2;Placebo
37 Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis Active, not recruiting NCT02466243 Phase 2 JBT-101;Placebo;JBT-101 Open-label
38 Basiliximab Treating Interstitial Pneumonia of CADM Not yet recruiting NCT03192657 Phase 2 Basiliximab;Calcineurin Inhibitors;Steroids
39 Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders Not yet recruiting NCT02418273 Phase 1, Phase 2 denosumab
40 Efficacy and Tolerability of BAF312 in Patients With Polymyositis Terminated NCT01801917 Phase 2 Placebo;BAF312
41 Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis Terminated NCT01148810 Phase 2 BAF312;Placebo
42 Infections and Autoimmunity: Autobodies Screening in Multiple Sclerosis Unknown status NCT00230204 Phase 1
43 A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis Completed NCT00533091 Phase 1
44 A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases Completed NCT02780674 Phase 1
45 Mycophenolate Mofetil in Systemic Sclerosis Completed NCT00433186 Phase 1 Mycophenolate Mofetil
46 A Pilot Study of Etanercept in Dermatomyositis Completed NCT00112385 Phase 1 Etanercept;Placebo
47 Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders Completed NCT00010335 Phase 1
48 Study of Tofacitinib in Refractory Dermatomyositis Recruiting NCT03002649 Phase 1 Tofacitinib
49 Dermatomyositis and Polymyositis Registry Unknown status NCT01637064 Acthar
50 Detection of Pompe Disease in Adult Patients With Myopathies of Uncertain Origin or With Asymptomatic Hyper-CK-emia Unknown status NCT01482494

Search NIH Clinical Center for Polymyositis

Genetic Tests for Polymyositis

Anatomical Context for Polymyositis

MalaCards organs/tissues related to Polymyositis:

38
Lung, Heart, Testes, Skeletal Muscle, T Cells, Bone, Breast

Publications for Polymyositis

Articles related to Polymyositis:

(show top 50) (show all 831)
# Title Authors Year
1
Role of Positron Emission Tomography-computed Tomography in a Case of Suspected Paraneoplastic Inflammatory Polymyositis with Urinary Bladder Tumor. ( 29430120 )
2018
2
Baseline peripheral blood neutrophil-to-lymphocyte ratio could predict survival in patients with adult polymyositis and dermatomyositis: A retrospective observational study. ( 29293605 )
2018
3
Increased risk of venous thromboembolism associated with polymyositis and dermatomyositis: a meta-analysis. ( 29416342 )
2018
4
The predictive prognostic factors for polymyositis/dermatomyositis-associated interstitial lung disease. ( 29325580 )
2018
5
Coexistence of anti-Jo1 and anti-signal recognition particle antibodies in a polymyositis patient. ( 29396013 )
2018
6
Clinical Heterogeneity of Interstitial Lung Disease in Polymyositis and Dermatomyositis Patients With or Without Specific Autoantibodies. ( 29289262 )
2018
7
Lipid-lowering agent-triggered dermatomyositis and polymyositis: a case series and literature review. ( 29027009 )
2018
8
Symptomatic arrhythmia in the form of multiple premature ventricular extrasystoles as the first symptom of polymyositis. ( 29380919 )
2018
9
Circulating plasma microRNA profiling in patients with polymyositis/dermatomyositis before and after treatment: miRNA may be associated with polymyositis/dermatomyositis. ( 29321815 )
2018
10
Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. ( 28993346 )
2018
11
Muscle Strength and Muscle Endurance During the First Year of Treatment of Polymyositis and Dermatomyositis: A Prospective Study. ( 29419464 )
2018
12
Roles of macrophage migration inhibitory factor in polymyositis: Inflammation and regeneration. ( 29239244 )
2018
13
A patient with pembrolizumab-induced fatal polymyositis. ( 29329695 )
2018
14
Anti-SS-A/Ro antibody positivity as a risk factor for relapse in patients with polymyositis/dermatomyositis. ( 28463039 )
2017
15
Efficacy and safety of adrenocorticotropic hormone gel in refractory dermatomyositis and polymyositis. ( 29237618 )
2017
16
Successful treatment of a refractory dysbiotic intestinal pseudo-obstruction in a patient with systemic sclerosis-polymyositis overlap syndrome by intravenous immunoglobulin administration possibly related to gut flora normalisation. ( 28229828 )
2017
17
Potential role of autophagy in Ta89cell survival in polymyositis and dermatomyositis. ( 28586060 )
2017
18
Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease. ( 28012490 )
2017
19
T-cell receptor-mediated characteristic signaling pathway of peripheral blood T cells in dermatomyositis and polymyositis. ( 29172719 )
2017
20
Dropped Head Syndrome and the Presence of Rimmed Vacuoles in a Muscle Biopsy in Scleroderma-Polymyositis Overlap Syndrome Associated with Anti-Ku Antibody. ( 29151520 )
2017
21
2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects. ( 28977549 )
2017
22
Juvenile dermatomyositis/polymyositis and lymphoma. ( 28477693 )
2017
23
Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients. ( 28283597 )
2017
24
Using multi-omics methods to understand dermatomyositis/polymyositis. ( 28778709 )
2017
25
Polymyositis without Beneficial Response to Steroid Therapy: Should Miyoshi Myopathy be a Differential Diagnosis? ( 28053302 )
2017
26
Paradoxical development of polymyositis-like autoimmunity through augmented expression of autoimmune regulator (AIRE). ( 28931462 )
2017
27
Upregulation of Interleukin 21 and Interleukin 21 Receptor in Patients with Dermatomyositis and Polymyositis. ( 28836555 )
2017
28
An efficacy analysis of whole-body magnetic resonance imaging in the diagnosis and follow-up of polymyositis and dermatomyositis. ( 28715432 )
2017
29
Acute heart failure and rhabdomyolysis: a clue for the diagnosis of polymyositis with cardiac involvement. ( 28776362 )
2017
30
GLIS3 and TYK2 Single Nucleotide Polymorphisms Are Not Associated with Dermatomyositis/Polymyositis in Chinese Han Population. ( 28846454 )
2017
31
Progressive hypoventilation due to mixed CD8(+) and CD4(+) lymphocytic polymyositis following tremelimumab - durvalumab treatment. ( 28716137 )
2017
32
A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis. ( 29174792 )
2017
33
Sarcoid Myopathy Mimicking Polymyositis: A Case Report and Pool Analysis of the Literature Reviews. ( 29373888 )
2017
34
Clinical Utility of YKL-40 in Polymyositis/dermatomyositis-associated Interstitial Lung Disease. ( 28711881 )
2017
35
State of the art on nailfold capillaroscopy in dermatomyositis and polymyositis. ( 28668440 )
2017
36
Cardiac function in patients with polymyositis or dermatomyositis: a three-dimensional speckle-tracking echocardiography study. ( 29168054 )
2017
37
Extensive Dystrophic Calcinosis Cutis: A Severe Complication of Polymyositis/Systemic Sclerosis Overlap Syndrome. ( 28926465 )
2017
38
Hypercapnic respiratory failure during pregnancy due to polymyositis-related respiratory muscle weakness: a case report. ( 28743311 )
2017
39
2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. ( 28385805 )
2017
40
Intense Muscle Activity Due to Polymyositis Incidentally Detected in a Patient Evaluated for Possible Malignancy by FDG PET/CT Imaging. ( 28604480 )
2017
41
Adult morphea en coup de sabre with accompanying regional polymyositis: A separate entity? ( 28731498 )
2017
42
Positive Association between ANKRD55 Polymorphism 7731626 and Dermatomyositis/Polymyositis with Interstitial Lung Disease in Chinese Han Population. ( 28470010 )
2017
43
Altered chemokine receptor expression in the peripheral blood lymphocytes in polymyositis and dermatomyositis. ( 28869080 )
2017
44
A review of inflammatory idiopathic myopathy focusing on polymyositis. ( 28816394 )
2017
45
Polymyositis with elevated serum IgG4 levels and abundant IgG4+ plasma cell infiltration: A case report and literature review. ( 29310344 )
2017
46
Successful treatment using rituximab in a patient with refractory polymyositis complicated by scleroderma renal crisis. ( 28942404 )
2017
47
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. ( 28382787 )
2017
48
Muscle ultrasound: a potential tool for detecting of fasciitis among dermatomyositis and polymyositis: Comment on article by Yoshida et al. ( 28853226 )
2017
49
Pregnancy outcomes in adult patients with dermatomyositis and polymyositis. ( 29217291 )
2017
50
Evaluation of coexisting polymyositis in feline myasthenia gravis: A case series. ( 28687435 )
2017

Variations for Polymyositis

Expression for Polymyositis

Search GEO for disease gene expression data for Polymyositis.

Pathways for Polymyositis

Pathways related to Polymyositis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.26 AARS GARS HARS IARS KARS
2 10.65 ICAM1 IL1A

GO Terms for Polymyositis

Cellular components related to Polymyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.7 AARS EXOSC9 GARS IARS ICAM1 MB
2 cytosol GO:0005829 9.32 AARS CHKB EXOSC9 GARS HARS IARS
3 aminoacyl-tRNA synthetase multienzyme complex GO:0017101 8.96 IARS KARS

Biological processes related to Polymyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to copper ion GO:0046688 9.37 ICAM1 IL1A
2 translation GO:0006412 9.35 AARS GARS HARS IARS KARS
3 regulation of translational fidelity GO:0006450 9.32 AARS IARS
4 aminoacyl-tRNA metabolism involved in translational fidelity GO:0106074 9.26 AARS IARS
5 diadenosine tetraphosphate biosynthetic process GO:0015966 9.16 GARS KARS
6 tRNA aminoacylation for protein translation GO:0006418 9.02 AARS GARS HARS IARS KARS

Molecular functions related to Polymyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.7 AARS CHKB GARS HARS IARS KARS
2 tRNA binding GO:0000049 9.43 AARS IARS KARS
3 amino acid binding GO:0016597 9.37 AARS KARS
4 ligase activity GO:0016874 9.35 AARS GARS HARS IARS KARS
5 aminoacyl-tRNA editing activity GO:0002161 9.32 AARS IARS
6 aminoacyl-tRNA ligase activity GO:0004812 9.02 AARS GARS HARS IARS KARS

Sources for Polymyositis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....